A number of factors are standing out as promoters for and protectors against the development of Alzheimer’s disease, according to research presented during the 2014 Alzheimer’s Association International Conference (AAIC) being held July 12-17 at the Bella Center in Copenhagen, Denmark.

Amino-acid biomarkers have undergone an evolution in the imaging of gliomas. Several agents have shown to be particularly useful, most notably C-11 MET, F-18 FDOPA, FLT and FET, according to a review of amino-acid imaging published July 8 in the Journal of Nuclear Medicine.

Preliminary research shows that O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) could be used as a biomarker for response to chemoradiotherapy in glioblastoma patients, the University of West Australia School of Medicine announced last week.

A preclinical imaging system that takes conventional microscopy and transforms it into a molecular imaging platform uses fluorescence and luminescence as well as radioisotope biomarkers and high resolution x-ray. The technique is called intravital microscopy, according to a study published online July 12 in Hepatology.

The Alzheimer's Association International Conference is schedule to be held July 12-17 at the Bella Center in Copenhagen, Denmark. The meeting will feature many scientific sessions, plenary sessions and symposia dedicated to the most up-to-date Alzheimer's disease research.

Specific genetic mutations in an ear-marked pathway now have been implicated in the development of lung adenocarcinoma, the most prevalent subtype of lung cancer, according to a study published online July 9 in Nature. The discovery of these mutations could hone drug targets for new therapies down the road.

UltraSpect, provider of the only multi-vendor and most cost-effective imaging solution for meeting the American Society of Nuclear Cardiology (ASNC) low dose guidelines, announces today that Henry Ford Wyandotte Hospital in Michigan has upgraded its nuclear medicine (NM) image reconstruction software to UltraSpect Xpress3.Cardiac. As a result, all patients receiving NM exams now have exams in half the time, with half the dose, regardless of the model or age of camera being used.

An annual financial report from Advanced Accelerator Applications (AAA) in Saint-Genis-Pouilly, France, announced yesterday that the company’s sales were up just over 30 percent to almost $80 million.